Charles Sternberg, Associate Editor05.03.22
Medartis Holding AG has completed the acquisition of Nextremity Solutions Inc., a strategic commercialization organization located in Warsaw, USA. The total purchase price for the transaction will be up to $70 million and includes milestone and earn-out payments of up to $30 million.
This acquisition, which was announced on March 7, 2022, will enable Medartis to further accelerate its U.S. extremities business by gaining access to a comprehensive product pipeline, strong relationships to U.S. design surgeons and an experienced R&D team. This transaction will provide significant growth opportunities in the U.S. extremities market and potentially in additional markets. Medartis also acquires a modern regional manufacturing base and a complementary leadership organization.
The acquisition of Nextremity Solutions Inc. (NSI) will be consolidated as of May 3. The first products with significant sales potential are expected to be launched in early 2023 and will therefore not have a material impact on the company’s sales guidance in 2022.
Medartis will continue to base its local organization in Exton (Pennsylvania, USA) and Warsaw (Indiana, USA). While manufacturing and R&D will be located at the former NSI headquarters, supply chain, customer service and other commercial activities will be based at the current Medartis USA site in Exton.
“I am honored and excited to lead the combined Medartis US team. We intend to build on our shared vision and common culture to deliver meaningful innovation for our customers. I believe this is an impactful combination that will support an attractive growth trajectory in the future,” commented Mayer.
Lisa C. Thompson, president North America, has decided to resign following the successful reorganization of the U.S. business and the acquisition of NSI. She will support Rod K. Mayer during the transition phase and plans to resume her consulting activities in the medical device industry.
CEO Christoph Brönnimann commented, “I am delighted that Rod Mayer and the rest of NSI's leadership team are complementing our U.S. organization. I would like to express my gratitude to Lisa for her dedication and commitment to this company. Lisa has repositioned our U.S. organization over the past two years, shaping it into a sustainable, competitive, and customer-centric sales organization. I wish her the very best in her future endeavors.”
This acquisition, which was announced on March 7, 2022, will enable Medartis to further accelerate its U.S. extremities business by gaining access to a comprehensive product pipeline, strong relationships to U.S. design surgeons and an experienced R&D team. This transaction will provide significant growth opportunities in the U.S. extremities market and potentially in additional markets. Medartis also acquires a modern regional manufacturing base and a complementary leadership organization.
The acquisition of Nextremity Solutions Inc. (NSI) will be consolidated as of May 3. The first products with significant sales potential are expected to be launched in early 2023 and will therefore not have a material impact on the company’s sales guidance in 2022.
Medartis will continue to base its local organization in Exton (Pennsylvania, USA) and Warsaw (Indiana, USA). While manufacturing and R&D will be located at the former NSI headquarters, supply chain, customer service and other commercial activities will be based at the current Medartis USA site in Exton.
Leadership Changes
As part of this merger, NSI’s CEO Rod K. Mayer is appointed president of Medartis U.S. as a non-executive member. Mayer is a highly-experienced industry expert with a long and distinguished track record in sales and product development in the medical devices industry. In his role, he will report directly to CEO Christoph Brönnimann and lead Medartis' U.S. organization, focusing specifically on leading the U.S. sales force.“I am honored and excited to lead the combined Medartis US team. We intend to build on our shared vision and common culture to deliver meaningful innovation for our customers. I believe this is an impactful combination that will support an attractive growth trajectory in the future,” commented Mayer.
Lisa C. Thompson, president North America, has decided to resign following the successful reorganization of the U.S. business and the acquisition of NSI. She will support Rod K. Mayer during the transition phase and plans to resume her consulting activities in the medical device industry.
CEO Christoph Brönnimann commented, “I am delighted that Rod Mayer and the rest of NSI's leadership team are complementing our U.S. organization. I would like to express my gratitude to Lisa for her dedication and commitment to this company. Lisa has repositioned our U.S. organization over the past two years, shaping it into a sustainable, competitive, and customer-centric sales organization. I wish her the very best in her future endeavors.”
